Brigham and Women's Hospital researchers developed a new nanomedicine, ADN, combining anticancer drugs and immune system enhancement, to treat lung cancer resistant to traditional immunotherapy.
Researchers from Brigham and Women's Hospital have developed a new nanomedicine therapy that combines anticancer drugs and immune system enhancement to treat lung cancer. The therapy, called antibody-conjugated drug-loaded nanotherapeutics (ADN), showed promising results in lab tests and mouse lung tumor models. It aims to improve care and outcomes for patients with tumors resistant to traditional immunotherapy. The findings are published in Science Advances.
June 14, 2024
3 Articles